Long-term clinical and cost-effectiveness of cognitive therapy for refractory social anxiety disorder: one-year follow-up of randomised controlled trial
Long-term clinical and cost-effectiveness of cognitive therapy for refractory social anxiety disorder: one-year follow-up of randomised controlled trial
复制标题
认知疗法治疗难治性社交焦虑症的长期临床和成本效益：随机对照试验的一年随访
DOI：
10.1159/000500108
复制
发表时间：
2019
影响因子：
22.8
通讯作者：
Shimizu E
中科院分区：
文献类型：
--
作者：
Yoshinaga N;Kubota K;Yoshimura K;Takanashi R;Ishida Y;Iyo M;Fukuda T;Shimizu E
有大量证据表明，抗抑郁药和认知疗法（CT）对社交焦虑障碍（SAD）的治疗有益[1]。尽管个体化CT最近被视为SAD的首选治疗方法，但抗抑郁药在临床实践中仍常用[2，3]。因此，需要更多的工作来收集抗抑郁药治疗无效的SAD的下一步治疗选择的证据。只有四项研究评估了抗抑郁药难治性SAD的增强或转换策略[4-7]。在这些下一步策略中，个体化CT作为常规治疗的辅助手段，在治疗结束时达到了最高的治疗应答率（85.7%）和缓解率（47.6%）[4]。相反，其他药物增强/转换策略的缓解率为48.3 - 70.0%，缓解率为18.6 - 27.0%[5-7]。然而，这些研究仅评估了短期治疗结果（最长为24周）。
There is a large body of evidence that antidepressants and cognitive therapy (CT) are beneficial for the treatment of social anxiety disorder (SAD)[1]. Although individual CT has recently been regarded as the first-choice treatment for SAD, antidepressants are still commonly used in clinical practice [2, 3]. Therefore, more work is required to garner evidence of next-step treatment options for SADs who have been ineffectively treated with antidepressants.Only four studies have assessed augmentation or switching strategies for SADs who were refractory to antidepressants [4-7]. Among these next-step strategies, individual CT as an adjunct to usual care has achieved the highest rates of treatment response (85.7%) and remission (47.6%) at the end of treatment [4]. Conversely, other medication augmentation/switching strategies had response rates of 48.3− 70.0% and remission rates of 18.6− 27.0%[5-7]. However, these studies have only assessed short-term treatment outcomes (the longest being 24 weeks).